Kathryn E. Giusti - Jan 1, 2023 Form 4 Insider Report for EQRx, Inc. (EQRX)

Role
Director
Signature
/s/ William Collins, Attorney-in-Fact
Stock symbol
EQRX
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 08:56 PM
Previous filing
Oct 4, 2022
Next filing
Nov 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EQRX Earn-out Shares Award +114 +0.52% 21.9K Jan 1, 2023 Common Stock 114 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 114 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 80 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 34 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).